Hemab Therapeutics (NASDAQ:COAG) Director Ra Capital Management, L.P. Purchases 2,675,000 Shares

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Director Ra Capital Management, L.P. acquired 2,675,000 shares of the stock in a transaction dated Monday, May 4th. The stock was bought at an average cost of $18.00 per share, with a total value of $48,150,000.00. Following the completion of the purchase, the director owned 6,149,096 shares of the company’s stock, valued at approximately $110,683,728. The trade was a 77.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, May 6th, Ra Capital Management, L.P. acquired 68,018 shares of Hemab Therapeutics stock. The stock was bought at an average cost of $24.60 per share, with a total value of $1,673,242.80.
• On Tuesday, May 5th, Ra Capital Management, L.P. acquired 97,411 shares of Hemab Therapeutics stock. The stock was bought at an average cost of $24.63 per share, with a total value of $2,399,232.93.

Hemab Therapeutics Stock Performance

Shares of Hemab Therapeutics stock opened at $25.01 on Thursday. Hemab Therapeutics Holdings, Inc. has a 52 week low of $23.48 and a 52 week high of $36.61.